Fasting - Glipizide, Metformin Interaction Details

Interaction Details

Glipizide, Metformin is classified as belonging to the following category: Antidiabetes Drugs

Fasting might increase the risk of hypoglycemia if used with antidiabetes drugs.
Hypoglycemic events have been reported during intermittent fasting, including in patients using antidiabetes drugs. The risk of having a hypoglycemic event is largest for patients taking insulin or sulfonylureas. The risk of hypoglycemic events seems to be lower for patients taking other antidiabetes drugs such as glucagon-like peptide-1 receptor agonist (GLP- 1RA), metformin, thiazolidinediones, dipeptidyl peptidase-4 inhibitors (DPP4 inhibitors), and sodium-glucose cotransporter-2 (SGLT2) inhibitors. Advise patients to monitor glucose levels closely. Dose or time adjustments may be necessary.

Interaction Rating

Moderate

Likelihood of Occurrence

Possible

Interaction has been documented in animal or in lab research, or the interaction has been documented in humans but is limited to case reports or conflicting clinical research exists

References

Carter S, Clifton PM, Keogh JB. Effect of intermittent compared with continuous energy restricted diet on glycemic control in patients with Type 2 diabetes: A randomized noninferiority trial. JAMA Netw Open. 2018;1(3):e180756.
Cioffi I, Evangelista A, Ponzo V, et al. Intermittent versus continuous energy restriction on weight loss and cardiometabolic outcomes: a systematic review and meta-analysis of randomized controlled trials. J Transl Med. 2018;16(1):371.
Chowdhury A, Khan H, Lasker SS, Chowdhury TA. Fasting outcomes in people with diabetes and chronic kidney disease in East London during Ramadan 2018: The East London diabetes in Ramadan survey. Diabetes Res Clin Pract. 2019;152:166-170.
Grajower MM, Horne BD. Clinical management of intermittent fasting in patients with diabetes mellitus. Nutrients. 2019;11(4):873.
Ibrahim M, Davies MJ, Ahmad E, et al. Recommendations for management of diabetes during Ramadan: update 2020, applying the principles of the ADA/EASD consensus. BMJ Open Diabetes Res Care. 2020;8(1):e001248.
Wang X, Li Q, Liu Y, Jiang H, Chen W. Intermittent fasting versus continuous energy-restricted diet for patients with type 2 diabetes mellitus and metabolic syndrome for glycemic control: A systematic review and meta-analysis of randomized controlled tria

Fasting - More Interactions

Fasting interacts with 205 drugs

Interaction Rating Key

These severity listings are for informational use only. Never start, stop or otherwise change your therapy before speaking with your provider.

Major	The combined use of these agents is strongly discouraged as serious side effects or other negative outcomes could occur.
Moderate	Use cautiously under the care of a healthcare professional or avoid this combination. A significant interaction or negative outcome could occur.
Minor	Be aware that there is a chance of an interaction. Watch for warning signs of a potential interaction.
Unknown	No interactions have been reported or no interaction data is currently available.